MedDRA preferred term

Blood calcium decreased: adverse event reports recording this term

11,097 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

11,097
reports recording the term: 0.1% of all reports; 479
reports, 12 months to June 2026: 491 in the 12 months before; 79.7%
marked serious by the reporter: 57.4% across all reports; 9.1%
record death among outcomes, as reported: 9.1% across all reports

11,097 reports in FDA's adverse event database record the MedDRA term "Blood calcium decreased": 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

479 reports recorded it in the 12 months to June 2026, close to the 491 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 79.7% are marked serious, 9.1% include death among the outcomes and 55.2% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Prolia, Omeprazole and Furosemide. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Prolia	RANK ligand inhibitor	702	0.5%
Omeprazole	Proton pump inhibitor	600	1%
Furosemide	Loop diuretic	587	1.2%
Carbamazepine	Mood stabilizer	559	2.5%
Revlimid	Thalidomide analog	534	0.2%
Oxazepam	Benzodiazepine	531	5%
Lactulose	Osmotic laxative	520	12.6%
Morphine sulfate	Opioid agonist	506	0.8%
Natpara	—	504	14.7%
Magnesium hydroxide	Calculi dissolution agent	490	44.2%
Acebutolol hydrochloride	beta-Adrenergic blocker	486	50.4%
Glucosamine	—	471	33.4%
Levothyroxine sodium	l-Thyroxine	466	3.2%
Cyclobenzaprine	Muscle relaxant	465	5.3%
Tiotropium bromide	Anticholinergic	461	0.6%
Levofloxacin	Fluoroquinolone antibacterial	446	1.5%
Nitroglycerin	Nitrate vasodilator	446	7.4%
Diltiazem hydrochloride	Calcium channel blocker	437	7.2%
Amitriptyline hydrochloride	Tricyclic antidepressant	427	9.5%
Dipyridamole	Platelet aggregation inhibitor	416	24.5%
Quinapril hydrochloride	Angiotensin converting enzyme inhibitor	404	42.9%
Aggrenox	—	368	13.1%
Dulcolax	Osmotic laxative	357	12.3%
Rosuvastatin calcium	HMG-CoA reductase inhibitor	354	4.5%
Galantamine hydrobromide	Cholinesterase inhibitor	350	30.1%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
RANK ligand inhibitor	1,012	0.6%	0.5%
Osmotic laxative	967	0.7%	0%
Kinase inhibitor	927	0.1%	0%
Proton pump inhibitor	920	0.2%	0%
Benzodiazepine	802	0.3%	0.1%
Nonsteroidal anti-inflammatory drug	767	0.1%	0%
Muscle relaxant	733	3.6%	0.4%
Opioid agonist	722	0.1%	0%
Calcium channel blocker	721	0.9%	0.1%
Thalidomide analog	694	0.1%	0.2%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.4%39

2 to 110.8%92

12 to 170.9%101

18 to 4410.6%1,175

45 to 6422.2%2,464

65 to 7415.2%1,687

75 and over16.5%1,835

Age not given33.4%3,704

Patient sex

Female61%6,773

Male30.9%3,430

Not given8.1%894

Grey bar: all 20,646,523 reports in the database. 60.4% of these reports give the United States as the country.

Questions about "Blood calcium decreased"

What does "Blood calcium decreased" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record blood calcium decreased?

11,097 reports through June 2026 (0.1% of all reports), 479 of them in the latest 12 months.

Which drugs appear most often in these reports?

Prolia (702), Omeprazole (600), Furosemide (587), Carbamazepine (559) and Revlimid (534). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.